Metal

AIDS Vaccines

Virology

Bivalent (engine)

Environmental health

HIV vaccine

Immunology

Organic chemistry

Regimen

Human immunodeficiency virus (HIV)

Vaccine trial

Population

Internal medicine

Medicine

Chemistry

New England Journal of Medicine

A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1–2a trial in South Africa. Efficacy data and additional safety data were needed for this regimen in a larger population in South Africa.

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults